DGX vs ILMN: fair value comparison
Quest Diagnostics Incorporated and Illumina, Inc. · Updated 2026-09-06
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ILMN currently sits closer to the top of our discount ranking.
| DGX | ILMN | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $237.14 | $198.16 |
| 12-month range | $173.79–$236.22 | $102.26–$198.16 |
| Sector rank | #103 of 113 Healthcare | #98 of 113 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: DGX fair value analysis · ILMN fair value analysis